Public Employees Retirement System of Ohio Makes New Investment in Insmed, Inc. $INSM

Key Points

• The Public Employees Retirement System of Ohio acquired a new stake in Insmed, Inc., purchasing 55,425 shares valued at approximately $5.58 million in the second quarter.
• Insider trading activity revealed that CEO William Lewis sold 6,865 shares for about $881,466, reflecting a 2.85% decrease in his ownership.
• Investment analysts have significantly increased their price targets for Insmed, with estimates now reaching as high as $172.00, while the stock maintains an average rating of "Moderate Buy."

Public Employees Retirement System of Ohio bought a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 55,425 shares of the biopharmaceutical company's stock, valued at approximately $5,578,000.

Several other large investors also recently modified their holdings of INSM. Adage Capital Partners GP L.L.C. grew its position in shares of Insmed by 109.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the period. Nuveen LLC bought a new position in Insmed in the first quarter valued at approximately $88,351,000. Duquesne Family Office LLC boosted its holdings in shares of Insmed by 130.7% in the first quarter. Duquesne Family Office LLC now owns 1,369,050 shares of the biopharmaceutical company's stock valued at $104,445,000 after buying an additional 775,580 shares during the period. 1832 Asset Management L.P. acquired a new position in shares of Insmed in the first quarter valued at approximately $37,214,000. Finally, Wellington Management Group LLP increased its position in shares of Insmed by 62.5% during the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company's stock worth $93,274,000 after acquiring an additional 470,401 shares in the last quarter.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the transaction, the chief executive officer directly owned 233,924 shares of the company's stock, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This trade represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 277,332 shares of company stock worth $33,842,327 in the last quarter. 3.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on INSM shares. Guggenheim boosted their price objective on shares of Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Morgan Stanley boosted their price target on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Truist Financial upped their price objective on Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. JPMorgan Chase & Co. increased their price objective on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a report on Wednesday, August 20th. Finally, Royal Bank Of Canada boosted their target price on Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $139.86.

Insmed Price Performance

Shares of NASDAQ INSM opened at $137.03 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The business has a 50-day moving average of $127.93 and a 200-day moving average of $96.77. The stock has a market capitalization of $28.97 billion, a price-to-earnings ratio of -24.00 and a beta of 0.96. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $149.08.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue was up 18.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.